Pura Vida Investments’s Pacific Biosciences PACB Stock Holding History

Pura Vida Investments’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-415,000	Closed	-$3.47M	–	84
2023 Q3	$3.47M	Buy	+415,000	New	+$4.74M	0.66%	43
2023 Q1	–	Sell	-100,000	Closed	-$818K	–	142
2022 Q4	$818K	Buy	+100,000	New	+$862K	0.04%	149
2022 Q1	–	Sell	-330,033	Closed	-$3.8M	–	273
2021 Q4	$6.75M	Sell	330,033 -10,110	-3%	-$244K	0.24%	98
2021 Q3	$8.69M	Sell	340,143 -131,634	-28%	-$3.9M	0.26%	102
2021 Q2	$16.5M	Sell	471,777 -115,178	-20%	-$3.35M	0.51%	42
2021 Q1	$19.6M	Sell	586,955 -189,075	-24%	-$6.62M	0.56%	35
2020 Q4	$20.1M	Sell	776,030 -223,970	-22%	-$3.81M	0.73%	29
2020 Q3	$9.87M	Buy	+1,000,000	New	+$5.76M	0.51%	42
2018 Q4	–	Sell	-303,734	Closed	-$1.64M	–	101
2018 Q3	$1.64M	Buy	+303,734	New	+$1.3M	0.35%	72

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pura Vida Investments's PACB Position: Q4 2023 in Review

Pura Vida Investments sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 415,000 shares — an estimated $3.47M sold.

Pura Vida Investments first reported a position in PACB in Q3 2018 and held it in 9 quarters. The position peaked at $20.1M in Q4 2020. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

Pura Vida Investments reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
Pura Vida Investments sold 415,000 Pacific Biosciences shares in Q4 2023, an estimated $3.47M.
Pura Vida Investments first reported a position in Pacific Biosciences in Q3 2018 and held it in 9 quarters.
Pura Vida Investments's Pacific Biosciences position peaked at $20.1M in Q4 2020.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Pura Vida Investments's 13F filing for Q4 2023, filed 13 Feb 2024.